Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
Association for the Treatment of Sexual Abusers of sexual abuse through effective treatment and management of sex offenders. It has approximately 3,000 members from 26 countries, with chapters throughout the United States and in Utrecht, Netherlands. Members include researchers, treatment providers, corrections officials, attorneys, law enforcement officers, and students. ATSA hosts the world's largest annual conference and leading educational venue for individuals working on issues related to the research, treatment, and management of sexual abuse. Conference locations vary each year. The official journal of ATSA is "Sexual Abuse", produced eight times a year. According to the Institute for Scientific Information, the peer-reviewed journal's 2016 impact factor was